Is Daprodustat a synthetic drug and an introduction to its production process?

Daprodustat is a synthetic small molecule drug developed by GlaxoSmithKline (GSK). It belongs to the oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) class of drugs. Its main mechanism of action is to promote the body's own production of erythropoietin (EPO) by inhibiting the degradation of HIF-related enzymes, thereby improving renal anemia. Therefore, daprostat is completely produced by chemical synthesis process, which is different from biological agents or naturally extracted drugs.

In terms of production technology, daporostat adopts a multi-step reaction process in the organic synthesis route, and its core structure is substituted phenylpyridones. The synthesis process usually includes multiple steps such as selective acylation, aromatic substitution reaction, nitrogen heterocycle construction, and reduction reaction. The starting materials are aromatic compounds that can be supplied industrially. By gradually introducing key functional groups, the target compound with HIF inhibitory activity is finally constructed. Each step of synthesis has higher requirements on reaction temperature, catalyst selection and product purification conditions to ensure the stability and biological activity of the final drug.

Since dapostat is an oral preparation, it has strict requirements on purity and crystal form control. Special attention will be paid to impurity control and crystal form screening technology during its production process. After the preparation of raw materials is completed, it is necessary to go through process steps such as crystallization, drying, crushing, and sieving to ensure that the pharmaceutical products meet the prescribed pharmacopoeia standards. In terms of preparations, they are most commonly produced in the form of tablets. The selection of excipients must take into account both stability and bioavailability, including the use of appropriate binders, disintegrants, and lubricants.
At present, daplestat has been approved in many countries for the treatment of anemia related to chronic kidney disease, but its domestic marketing and production are still in the gradual advancement stage. As a fully synthetic drug, daprostat has the advantages of mass production and consistency evaluation, laying the foundation for its global promotion and development of generic drugs. In the future, as the patent gradually expires, the disclosure of its synthesis route will also promote more generic drug companies to participate in production, bringing more accessible treatment options to patients.
Reference: https://en.wikipedia.org/wiki/Daprodustat